Added to YB: 2024-02-02
Pitch date: 2024-02-01
CRBU [bullish]
Caribou Biosciences, Inc.
-72.67%
current return
Author Info
No bio for this author
Company Info
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.
Market Cap
$184.8M
Pitch Price
$6.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.37
P/E
-1.17
EV/Sales
5.50
Sector
Biotechnology
Category
growth
Caribou Biosciences: Under The Radar With Catalysts Approaching
CRBU a strong buy: Positive off-the-shelf CAR-T CB-010 progress, pivotal trial for 2L LBCL by YE24. More ANTLER data Q2, CB-011 MM data YE24. Manageable toxicity, effective lower doses. CB-012 clinical H1. $370M+ cash YE23, EV <$200M. Risks: Weak ANTLER/CB-011 data, CB-012 tox.
Read full article (4 min)